Holmes E C, Gail M
J Clin Oncol. 1986 May;4(5):710-5. doi: 10.1200/JCO.1986.4.5.710.
The Lung Cancer Study Group randomized 141 patients with resected stage II and III adenocarcinoma and large-cell undifferentiated carcinoma to receive postoperative Cytoxan (Bristol-Meyers, Syracuse, NY), Adriamycin (Adria Laboratories, Columbus, Ohio), and cisplatin (CAP) chemotherapy or bacillus Calmette-Guerin (BCG) and levamisole immunotherapy. Careful intraoperative staging was performed on all patients. Before randomization, patients were stratified by stage, weight loss, cardiac arrhythmia, and institution. Prognostic variables such as stage, age, weight loss, and nodal involvement were equally distributed between the two groups. Disease-free survival was significantly prolonged in the group receiving chemotherapy. There was no evidence of a deleterious effect of the immunotherapy. This study indicates that postoperative CAP chemotherapy is effective in prolonging disease-free survival in these patients.
肺癌研究组将141例已切除的Ⅱ期和Ⅲ期腺癌及大细胞未分化癌患者随机分为两组，一组接受术后环磷酰胺（由纽约锡拉丘兹的百时美施贵宝公司生产）、阿霉素（由俄亥俄州哥伦布的阿德里亚实验室生产）和顺铂（CAP）化疗，另一组接受卡介苗（BCG）和左旋咪唑免疫治疗。所有患者均进行了仔细的术中分期。随机分组前，患者按分期、体重减轻、心律失常和机构进行分层。两组之间，诸如分期、年龄、体重减轻和淋巴结受累等预后变量分布均衡。接受化疗的组无病生存期显著延长。没有证据表明免疫治疗有有害作用。这项研究表明，术后CAP化疗可有效延长这些患者的无病生存期。
